Bg pattern

GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

GalliaPharm 0.74 - 1.85 GBq radionuclide generator

Gallium (68Ga) chloride solution

Read all of this leaflet carefully before you receive this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your nuclear medicine doctor who will supervise the procedure.
  • If you experience any side effects, talk to your nuclear medicine doctor, even if they are not listed in this leaflet. See section 4.

Contents of the package leaflet:

  1. What is GalliaPharm and what is it used for
  2. What you need to know before you start using the gallium (68Ga) chloride solution obtained with GalliaPharm
  3. How to use the gallium (68Ga) chloride solution obtained with GalliaPharm
  4. Possible side effects
  5. Storage of GalliaPharm
  6. Package contents and further information

1. What is GalliaPharm and what is it used for

This medicine is a radiopharmaceutical for diagnostic use only.

This medicine is a radiopharmaceutical that must not be administered directly to patients.

GalliaPharm is a germanium (68Ge) / gallium (68Ga) radionuclide generator, a device used to obtain a gallium (68Ga) chloride solution.

The gallium (68Ga) chloride solution is used for radiolabeling, a technique where labeling (radiolabeling) is performed with a radioactive compound, in this case 68Ga.

GalliaPharm is used to label certain medicines that have been developed and approved specifically for use with the active ingredient gallium (68Ga) chloride. These medicines act as carriers to carry the radioactive 68Ga to where it is needed. These may be substances designed to recognize a specific type of cell in the body, including tumor cells (cancer). The small amount of radioactivity administered can be detected outside the body using special cameras to obtain body images. Refer to the package leaflet of the medicine that will be radiolabeled with gallium (68Ga) chloride. Your nuclear medicine doctor will explain what kind of examination will be performed with this product.

Administration of a medicine labeled with 68Ga involves receiving a small amount of radioactivity. Your doctor and nuclear medicine doctor have considered that the clinical benefit you will obtain from the procedure with the radiopharmaceutical outweighs the risk of radiation.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you start using the gallium (68Ga) chloride solution obtained with GalliaPharm

The gallium (68Ga) chloride solution obtained with GalliaPharm must not be administered

  • if you are allergic to gallium (68Ga) chloride or any of the other components of this medicine (listed in section 6).

If you are using a medicine labeled with 68Ga, you should read the information on contraindications in the package leaflet of the medicine that will be radiolabeled.

Warnings and precautions

For information related to special warnings and precautions for the use of medicines labeled with 68Ga, refer to the package leaflet of the medicine that will be radiolabeled.

Children and adolescents

Tell your nuclear medicine doctor if you or your child is under 18 years old.

Other medicines and the gallium (68Ga) chloride solution

Tell your nuclear medicine doctor if you are taking, have recently taken, or might take any other medicine, as some medicines may interfere with the interpretation of the images.

It is not known if the gallium (68Ga) chloride solution can interact with other medicines, as no specific studies have been conducted.

For information related to interactions associated with the use of medicines labeled with 68Ga, refer to the package leaflet of the medicine that will be radiolabeled.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your nuclear medicine doctor before administering medicines labeled with GalliaPharm.

You must inform your nuclear medicine doctor before administration of medicines labeled with GalliaPharm if there is any possibility that you may be pregnant, if you have a delayed period, or if you are breastfeeding.

In case of doubt, it is important that you consult your nuclear medicine doctor who will supervise the procedure.

If you are pregnant

Your nuclear medicine doctor will only administer this medicine during pregnancy if the expected benefit outweighs the risk.

If you are breastfeeding

You will be asked to stop breastfeeding. Ask your nuclear medicine doctor when you can resume breastfeeding.

Driving and using machines

There may be effects on the ability to drive and use machines due to the medicine used in combination with GalliaPharm. Read the package leaflet of that medicine carefully.

3. How to use the gallium (68Ga) chloride solution obtained with GalliaPharm

There are strict rules on the use, handling, and disposal of radiopharmaceuticals. GalliaPharm will only be used in special controlled areas. This product will only be handled and administered by trained and qualified personnel to use it safely. These people will take special care in the safe use of this product and will inform you of their actions.

The nuclear medicine doctor who supervises the procedure will decide the amount of medicine labeled with GalliaPharm to be used in your case. This will be the minimum amount necessary to obtain the desired information, depending on the final product and its intended use. For more information, read the package leaflet of the medicine that will be radiolabeled.

Administration of the gallium (68Ga) chloride solution and performance of the procedure

You will not receive the gallium (68Ga) chloride solution, but another product labeled with GalliaPharm. The gallium (68Ga) chloride solution must only be used in combination with another medicine that has been developed and approved specifically for combination (radiolabeling) with GalliaPharm. You will only receive the final labeled product.

Duration of the procedure

Your nuclear medicine doctor will inform you about the usual duration of the procedure after administration of the medicine labeled with GalliaPharm.

After administration of the medicine labeled with GalliaPharm:

Your nuclear medicine doctor will inform you if you need to take special precautions after administration of the medicine labeled with GalliaPharm. Consult your nuclear medicine doctor if you have any doubts.

If you have been administered more medicine labeled with GalliaPharm than you should:

Overdose is unlikely, as you will only receive the medicine labeled with GalliaPharm under the precise control of the nuclear medicine doctor who supervises the procedure. However, in case of overdose, you will receive the appropriate treatment.

If you have any further questions about the use of this product, ask your nuclear medicine doctor who supervises the procedure.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, the medicine labeled with GalliaPharm can cause side effects, although not everybody gets them.

Administration of the medicine labeled with GalliaPharm involves receiving a small amount of ionizing radiation with a very low risk of developing cancer and genetic disorders.

Reporting of side effects

If you experience any side effects, talk to your nuclear medicine doctor, even if they are not listed in this leaflet.

You can also report side effects directly to the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of GalliaPharm

You will not need to store this medicine. This medicine is stored under the responsibility of the specialist in suitable facilities. The storage of radiopharmaceuticals will be carried out in accordance with national regulations on radioactive materials.

The following information is intended for healthcare professionals only.

The radionuclide generator must not be used after the expiry date stated on the packaging after "EXP".

Do not dismantle the box. Do not store above 25°C.

The gallium (68Ga) chloride solution obtained with GalliaPharm must be used immediately.

6. Package contents and further information

Composition of GalliaPharm

The active substance is gallium (68Ga) chloride solution.

The other components are: Titanium dioxide (matrix), Hydrochloric acid 0.1 mol/l sterile ultrapure (elution solution)

Appearance of GalliaPharm and package contents

You will not receive or handle this medicine.

Marketing authorization holder and manufacturer

Eckert & Ziegler Radiopharma GmbH

Robert-Rössle-Str. 10

13125 Berlin

Germany

Local representative:

NUCLIBER, S.A.

C/ Hierro, 33

28045 Madrid

Spain

Tel.: +34 915 062 940

This medicine is authorized in the Member States of the European Economic Area under the following names:

Country

Product name

Germany

GalliaPharm

Austria

GalliaPharm 0.74 - 1.85 GBq Radionuklidgenerator

Belgium

GalliaPharm, 0.74 - 1.85 GBq, radionuclide generator

GalliaPharm, 0.74 à 1.85 GBq, générateur radiopharmaceutique

GalliaPharm, 0.74 – 1.85 GBq, Radionuklidgenerator

Denmark

GalliaPharm

Slovakia

GalliaPharm

Spain

GalliaPharm 0.74 - 1.85 GBq radionuclide generator

Finland

GalliaPharm

France

GalliaPharm

Ireland

GalliaPharm

Italy

Germanium (68Ge) / Gallium (68Ga) chloride GalliaPharm

Latvia

GalliaPharm

Norway

GalliaPharm

Netherlands

GalliaPharm, 0.74 - 1.85 GBq, radionuclide generator

Poland

GalliaPharm

United Kingdom

GalliaPharm

Czech Republic

GalliaPharm

Sweden

Germanium (Ge-68) tetrachloride / Gallium (Ga-68) trichloride Eckert & Ziegler

Date of last revision of this leaflet: 12/2019.

-----------------------------------------------------------------------------------------------------------------

This information is intended for healthcare professionals only:

The full technical specifications of GalliaPharm are provided in a separate document in the product packaging, with the aim of providing healthcare professionals with additional scientific and practical information on the administration and use of this radiopharmaceutical.

Please refer to the technical specifications [the technical specifications must be included in the box].

Online doctors for GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR

Discuss questions about GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Томаш Гжеловський

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60
5.0 (29)
Doctor

Dmytro Horobets

Family medicine 7 years exp.

Dr. Dmytro Horobets is a licensed family medicine physician in Poland, specialising in endocrinology, diabetology, obesity management, gastroenterology, pediatrics, general surgery, and pain medicine. He offers online consultations for adults and children, providing personalised medical support for a wide range of acute and chronic health concerns.

Areas of expertise:

  • Endocrinology: diabetes type 1 and type 2, prediabetes, thyroid disorders, metabolic syndrome, hormonal imbalance.
  • Obesity medicine: structured weight management plans, nutritional counselling, obesity-related health risks.
  • Gastroenterology: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), liver and biliary conditions.
  • Pediatric care: infections, respiratory symptoms, digestive issues, growth and development monitoring.
  • General surgery support: pre- and post-surgical consultations, wound care, rehabilitation.
  • Pain management: chronic and acute pain, back pain, joint pain, post-traumatic pain syndromes.
  • Cardiovascular health: hypertension, cholesterol control, risk assessment for heart disease.
  • Preventive medicine: regular check-ups, health screenings, long-term management of chronic conditions.

Dr. Horobets combines evidence-based medicine with a patient-centred approach. He carefully evaluates each patient’s medical history and symptoms, offering clear explanations and structured treatment plans adapted to individual needs.

Whether you need help managing diabetes, tackling weight-related health issues, interpreting lab results, or receiving general family medicine support, Dr. Horobets provides professional online care tailored to your specific health goals.

Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR?
GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
Who manufactures GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR?
GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR is manufactured by Eckert & Ziegler Radiopharma Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to GALLIAPHARM 0.74 - 1.85 GBq RADIONUCLIDE GENERATOR?
Other medicines with the same active substance () include NORCOLESTEROL IODINATED (131 I) CIS BIO INTERNATIONAL 7.5-15 MBq/ml INJECTABLE SOLUTION, ADREVIEW 74 MBq/ml INJECTABLE SOLUTION, AMYVID 1.900 MBq/ml injectable solution. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media